ZEISS
The Power List 2020 – Power List
James V. (Jim) Mazzo
Global President Ophthalmic Devices
What has been your career highlight?
A number of achievements stand out for me throughout my career, from creating and becoming the Chairman/CEO of AMO, to my involvement in establishing the Gavin Herbert Eye Institute for fighting blindness and serving on the board of a number of organizations including ASCRS, AAO and NASA’s Mission to Mars Committee.
More recently, I am pleased to have been presented with the 2020 Ellis Island Medal, which recognizes the importance of immigration to America’s prosperity. The medal is presented annually to those who have shown an outstanding commitment to serving our nation either professionally, culturally or civically, among other criteria.
What are the biggest unmet needs in your field? How is ZEISS working to address them?
One of the biggest unmet needs in ophthalmology is the growing number of patients and decreasing number of clinicians, which means that doctors end up spending insufficient time with all types of patients, when limited clinic hours would be better suited focusing on patients that need the most help. ZEISS is continuing to develop technologies that produce, capture, display and analyze patient data across diagnostics and treatment products to help doctors identify patient needs before they get to the office or operating room – enabling them to make more efficient use of their time. Another unmet need is having solutions that work seamlessly across the full continuum of care, from the physician’s office to the operating room. From diagnostics to treatment, ZEISS is looking to adapt its technology to different solution designs using the information output as the constant and the devices as vehicles for care.
What should we expect from ZEISS over the next five years?
ZEISS has had a tremendous few years, but we are always looking for ways toimprove our service. We are expanding our digital footprint, continuing expansion in the USA, and will carry out further development by investing in R&D.
However, the real focus in the future will be on physicians making informed decisions right before or during surgery. Digital, data-driven technology that enables quick decisions is what will move us forward. The strength of ZEISS is that we are the only company that can diagnose, treat and manage. All ZEISS products are talking to each other, and with every piece of data online, doctors will be empowered to make better decisions. Our products will also enable doctors to be proactive in determining which patients can use self-diagnosis devices to cut down office visits, allowing for the best care possible.
